Evidence map›Paper›PMID 40395918›Full record

ArticleJuntendo medical journal2025

Co-occurrence of Down Syndrome and Multiple Sclerosis.

Yasuhiro Arai, Chihiro Mano

Abstract readCase Reports
In one paragraph

Article in Juntendo medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yasuhiro Arai
Chihiro Mano

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Object: Down syndrome (DS) is often associated with autoimmune diseases; however, its association with multiple sclerosis (MS) has rarely been reported. In a previous report, the coincidence of DS and MS showed a negative association. Here, we searched for the coincidence of DS and MS, and attempted to resolve this negative association, focusing on the gene dosage effect, by utilizing available reports. Case presentation: A 44-year-old woman with DS experienced a progressively worsening gait at onset. Auto-immuno-antibodies including aquaporin-4 antibody were negative. On the basis of brain magnetic resonance image (MRI) findings, the patient was diagnosed with possible MS. After three years, the patient demonstrated additional signs and regression symptoms. Re-examined brain MRI showed multiple new focal lesions. Based on the McDonald criteria, the patient was diagnosed with laboratory-supported defined MS. Discussion: To date, we have found only one case report in the literature describing the development of MS in a 49-year-old man with DS. The protective effect of DS against the development of MS might be mediated by a gain of function due to a gene dosage effect, and the effect of candidate antigens could be interferon alpha and beta receptors, S100B, and amyloid precursor protein (APP). Conclusions: In patients with DS, S100B and APP overexpression could protect against MS, but both correlate with the progression of Alzheimer's neuropathological changes. S100B and APP can be seemed to be multiple pathogenesis and co-occurrence of MS with DS and Alzheimer's dementia may advance more severely than MS without DS.

Indexed as

Down syndromegene dosage effectmultiple sclerosis

Identifiers

PMID40395918
PMCPMC12086456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.